LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

LLY

1,020.07

-1.55%↓

JNJ

244.95

+0.71%↑

ABBV

228.53

-1.79%↓

NVS

165.17

-0.6%↓

MRK

121.6

+0.04%↑

Search

Palvella Therapeutics Inc

Suletud

SektorTervishoid

78.92 -0.44

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

76.51

Max

79.82

Põhinäitajad

By Trading Economics

Soovitused

By TipRanks

Soovitused

Tugev "osta" hinnang

12 kuu keskmine prognoos

+120.04% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

30. märts 2026

Uudiste sentiment

By Acuity

50%

50%

165 / 351 Pingereas Healthcare

Palvella Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

18. veebr 2026, 22:31 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1st Half Profit Jumps -- Update

18. veebr 2026, 22:18 UTC

Tulu

Wal-Mart de Mexico 4Q Profit Falls, Hit by Higher Taxes

18. veebr 2026, 22:11 UTC

Tulu

Wesfarmers Boosts Dividend After 1st Half Profit Rises -- Update

18. veebr 2026, 21:52 UTC

Tulu

Telstra Boosts Dividend as First-Half Earnings Rise 5.5% -- Update

18. veebr 2026, 23:56 UTC

Market Talk

Santos's Review of Domestic Assets Could Lead to Simpler Portfolio -- Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

18. veebr 2026, 23:46 UTC

Market Talk

Nikkei May Rise After U.S. Tech Stock Gains -- Market Talk

18. veebr 2026, 23:34 UTC

Market Talk
Tulu

Brambles' Cost Control Stands Out to Bull -- Market Talk

18. veebr 2026, 23:33 UTC

Market Talk

Gold Edges Higher Amid Growing Risks of U.S.-Iran Conflict -- Market Talk

18. veebr 2026, 23:32 UTC

Market Talk

Australia Jobs Data Will Likely Support May Hike Assumptions -- Market Talk

18. veebr 2026, 22:45 UTC

Tulu

DoorDash Stock Rebounds. Earnings and Revenue Both Fall Short. -- Barrons.com

18. veebr 2026, 22:44 UTC

Market Talk

Investors Eyeing Nvidia's Revenue Visibility Ahead of 4Q Print -- Market Talk

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q EPS $1.18 >NTR.T

18. veebr 2026, 22:37 UTC

Tulu

Nutrien 4Q Sales $5.34B >NTR.T

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q EPS $1.07 >PAAS

18. veebr 2026, 22:35 UTC

Tulu

Pan American Silver 4Q Rev $1.18B >PAAS

18. veebr 2026, 22:30 UTC

Tulu

Kinross Gold Raises Quarterly Dividend to 4c Vs. 3.5c >K.T

18. veebr 2026, 22:29 UTC

Tulu

Kinross Gold 4Q EPS 75c >K.T

18. veebr 2026, 22:22 UTC

Tulu

Coeur Mining: Full-Yr 2026 Production Is Expected to Be 55,000 - 65,000 Ounces of Gold and 5.5M - 6.3M Ounces of Silver >CDE

18. veebr 2026, 22:22 UTC

Market Talk

Nvidia 4Q Earnings Coming Amid China Export Battle -- Market Talk

18. veebr 2026, 22:16 UTC

Tulu

Brambles Raises Dividend, Cash-Flow Guidance as 1H Profit Jumps -- Update

18. veebr 2026, 22:05 UTC

Tulu

Pan American Silver Reports Record Fourth Quarter And Full Year 2025 Financial Results; Record Cash Flow From Operations Of $554 Million In The Fourth Quarter; Dividend Increased By 29% >PAAS

18. veebr 2026, 22:03 UTC

Tulu

Kaiser Aluminum Expects to Improve Conversion Rev by 5% to 10% and Adj EBITDA by 5% to 15% for FY26 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Adj EPS $1.53 >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q Sales $929M >KALU

18. veebr 2026, 22:02 UTC

Tulu

Kaiser Aluminum 4Q EPS $1.68 >KALU

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Adj EPS 67c >KGC

18. veebr 2026, 22:00 UTC

Tulu

Kinross Gold 4Q Sales $2.02B >KGC

18. veebr 2026, 21:56 UTC

Tulu

Wesfarmers Boosts Dividend After 1H Profit Rises -- Update

18. veebr 2026, 21:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Palvella Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

120.04% tõus

12 kuu keskmine prognoos

Keskmine 179.42 USD  120.04%

Kõrge 212 USD

Madal 76.43 USD

Põhineb 15 Wall Streeti analüütiku instrumendi Palvella Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

15 ratings

15

Osta

0

Hoia

0

Müü

Sentiment

By Acuity

165 / 351 Pingereas Tervishoid

Uudiste sentiment

Neutral

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Üle keskmise

Finantsandmed

$

help-icon Live chat